Top Page
Otsuka Holdings Co
(OTC:4578)
Otsuka Holdings Co (4578) vs. S&P 500 (SPY)
Otsuka Holdings Co Business Overview & Revenue Model
Otsuka Holdings Co Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.33T | 2.02T | 1.74T | 1.50T | 1.42T | Gross Profit |
| 1.67T | 1.41T | 1.17T | 1.00T | 983.08B | EBIT |
| 323.56B | 139.61B | 220.54B | 154.50B | 198.58B | EBITDA |
| 452.62B | 224.20B | 279.83B | 231.43B | 291.03B | Net Income Common Stockholders |
| 343.12B | 121.62B | 133.91B | 125.46B | 148.14B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 426.17B | 513.34B | 489.12B | 430.76B | 401.77B | Total Assets |
| 3.74T | 3.36T | 3.10T | 2.82T | 2.63T | Total Debt |
| 189.38B | 214.19B | 194.16B | 212.45B | 226.08B | Net Debt |
| -236.79B | -299.15B | -277.47B | -198.23B | -130.77B | Total Liabilities |
| 961.09B | 924.93B | 840.17B | 775.73B | 744.38B | Stockholders Equity |
| 2.73T | 2.39T | 2.23T | 2.01T | 1.85T |
| Cash Flow | Free Cash Flow | |||
| 225.28B | 168.56B | 104.06B | 115.71B | 134.96B | Operating Cash Flow |
| 354.64B | 283.23B | 211.85B | 228.86B | 232.84B | Investing Cash Flow |
| -268.27B | -190.54B | -81.58B | -95.29B | -99.86B | Financing Cash Flow |
| -186.89B | -60.17B | -95.47B | -95.84B | -104.93B |
Otsuka Holdings Co Technical Analysis
Otsuka Holdings Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $14.17T | 34.58 | 22.80% | 1.15% | 17.96% | 25.65% | |
79 Outperform | $2.63T | 51.43 | 3.22% | 5.10% | 19.25% | 294.48% | |
72 Outperform | $4.13T | 11.83 | 13.46% | 1.55% | 14.52% | 156.70% | |
68 Neutral | $7.00T | 33.49 | 1.50% | 4.47% | 9.83% | 15.49% | |
65 Neutral | $1.20T | 20.65 | 6.83% | 3.72% | 5.63% | 30.61% | |
54 Neutral | ¥382.99B | ― | -68.59% | ― | 12.84% | -1.34% | |
52 Neutral | $5.15B | 3.56 | -42.52% | 2.83% | 14.56% | -0.53% |
Otsuka Holdings Co Earnings Call Summary
Otsuka Holdings Co Corporate Events
Otsuka Holdings Co., Ltd. announced a change in its major shareholder structure due to a partial refund of shares by members of the Otsuka Founders Shareholding Fund. This adjustment has led to a slight decrease in the voting rights ratio of the major shareholder, The Nomura Trust and Banking Co., Ltd., but it will not impact the company’s management or business performance.
Otsuka Holdings Co., Ltd. reported a significant increase in revenue and profits for the first quarter of 2025, with revenue rising by 12.2% and operating profit by 35.2% compared to the same period in the previous year. Despite the positive financial performance, the company’s total comprehensive income saw a sharp decline of 96.9%. The company also announced the acquisition of Araris Biotech AG, indicating a strategic move to expand its scope of operations.
Otsuka Holdings Co., Ltd. announced a correction to a previous disclosure regarding the establishment of a joint venture between Otsuka Pharmaceutical Factory, Inc. and ICU Medical. The correction involved an error in the stated capital of ICU Medical, which was initially reported as USD2.04 billion and has been corrected to USD2.45 million. This correction ensures accurate financial reporting and maintains transparency with stakeholders.
Otsuka Holdings Co., Ltd. has completed the payment for the disposal of 88,340 treasury shares as part of its restricted stock compensation plan. This move is aimed at aligning the interests of its directors with those of the company, potentially impacting its governance and stakeholder relations positively.
Otsuka Holdings Co., Ltd. has completed a significant share repurchase and announced the cancellation of a portion of its treasury stock. This strategic move, involving the repurchase of over 9 million shares, aims to optimize the company’s capital structure and potentially enhance shareholder value.
Otsuka Holdings Co., Ltd. has announced the repurchase of 7,510,800 shares of its common stock, amounting to approximately 59 billion yen, as part of a resolution made by its Board of Directors. This strategic move, executed through market purchases on the Tokyo Stock Exchange, is aimed at optimizing the company’s capital structure and potentially enhancing shareholder value.
Otsuka Holdings Co., Ltd. has submitted a Biologics License Application to the FDA for sibeprenlimab, a monoclonal antibody designed to treat immunoglobulin A nephropathy (IgAN), a chronic kidney disease. This submission, supported by successful clinical trials, marks a significant step in providing a new treatment option that could potentially alter the course of IgAN, offering patients the convenience of home administration and addressing a critical unmet medical need.
Otsuka Holdings Co., Ltd. has announced a plan to dispose of treasury shares as part of a restricted stock compensation plan aimed at incentivizing directors to achieve medium- to long-term corporate goals. This move is expected to align the interests of directors with those of shareholders and enhance corporate value, with implications for the company’s operational strategy and stakeholder engagement.
Otsuka Holdings Co., Ltd. announced a correction to its previous disclosure regarding Taiho Pharmaceutical’s acquisition of Araris Biotech, a next-generation ADC drug discovery company. The correction involved changes in the details of major shareholders and shareholding ratios, highlighting the involvement of 4BIO Ventures II L.P. instead of 4BIO Partners LLP. This correction ensures accurate representation of the stakeholders involved in the acquisition, which could influence the strategic positioning of Otsuka Holdings in the pharmaceutical industry.
Otsuka Holdings Co., Ltd. announced a change in its major shareholders following a share repurchase on March 19, 2025. The Nomura Trust and Banking Co., Ltd., specifically the Otsuka Founder’s Shareholding Association Trust Account, remains a significant shareholder with a slight increase in its voting rights ratio, although its ranking among major shareholders remains unchanged. This change is not expected to impact the company’s management or business performance.
Otsuka Holdings Co., Ltd. has completed a significant share repurchase of 7,380,000 shares, amounting to approximately 57.95 billion yen, through the ToSTNeT-3 system. This strategic move is part of a broader plan to repurchase up to 12 million shares or 70 billion yen worth of stock by April 30, 2025, as approved by their Board of Directors. This initiative is likely to impact the company’s stock value and enhance shareholder returns.
Otsuka Holdings Co., Ltd. announced a board-approved plan to repurchase up to 8,914,900 of its own shares, representing 1.66% of total shares, through the Tokyo Stock Exchange’s off-auction trading system. This strategic move, with a maximum repurchase price of ¥70 billion, aims to optimize capital structure and enhance shareholder value, although actual repurchase may vary based on market conditions.
Otsuka Holdings Co., Ltd. has announced a strategic move to repurchase and subsequently cancel its own shares, aiming to enhance capital efficiency and return profits to shareholders. This decision, approved by the Board of Directors, involves repurchasing up to 12 million shares, representing 2.23% of the total shares outstanding, with a maximum repurchase price of ¥70 billion. The repurchase will occur between March 19 and April 30, 2025, with the cancellation of these shares scheduled for May 23, 2025. This move is expected to positively impact the company’s financial structure and shareholder value.
Otsuka Holdings Co., Ltd. announced that its subsidiary, Taiho Pharmaceutical, will acquire Swiss biotech company Araris Biotech AG for $400 million, with potential additional milestone payments of up to $740 million. This acquisition will enhance Taiho’s capabilities in developing next-generation ADCs, strengthening its oncology portfolio and positioning it as a leader in innovative cancer therapies.
Otsuka Holdings Co., Ltd. reported a significant increase in their nonconsolidated financial results for the year ended December 31, 2024, compared to the previous year. The rise in operating revenue, operating income, ordinary income, and net profit was largely attributed to increased dividends received from subsidiaries, indicating a robust financial performance that enhances the company’s market positioning and profitability.
Otsuka Holdings Co., Ltd. reported significant financial growth for the fiscal year ended December 31, 2024, with a revenue increase of 15.4% and a substantial rise in profits. The company’s strategic investments and operational efficiencies have resulted in improved financial metrics, enhancing its competitive positioning in the industry. The inclusion of Jnana Therapeutics Inc. in its consolidation scope indicates ongoing strategic expansion, which could have positive implications for stakeholders.
Otsuka Holdings Co. has announced its approach to potentially lower the stock investment unit to create a more investable environment for individual investors. The company plans to consider various factors, including market trends and shareholder composition, before deciding on specific measures such as stock splits.